Flexion Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2007-01-01
- Employees
- 257
- Market Cap
- -
Gene Therapy for Osteoarthritis Shows Promising Results in Phase 1 Trial
• A gene therapy developed at Baylor College of Medicine, PCRX-201, is showing promising results in Phase 1 clinical trials for osteoarthritis.
• The therapy utilizes a high-capacity adenovirus vector to deliver interleukin-1 receptor antagonist (IL-1Ra) to reduce inflammation in the knee joint.
• Phase 1 trial data indicates sustained improvements in knee pain, stiffness, and function up to 104 weeks following local administration of PCRX-201.
• Pacira BioSciences plans to initiate a Phase 2, double-blind, active-controlled study to further evaluate the efficacy of PCRX-201.
© Copyright 2025. All Rights Reserved by MedPath